NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register

NCT05413044

CompletedN/A

Sponsor: Bristol-Myers Squibb

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis

Countries: United States

The purpose of this study is to collect real-world data in order to estimate the frequency of overall malignancies, melanoma, basal cell carcinoma, and squamous cell carcinoma in participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) enrolled in the SRQ Register in Sweden.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosis of RA or PsA
* ≥18 years at index treatment initiation
* Participants starting treatment with:
* abatacept
* non-targeted DMARDs
* targeted DMARD

Exclusion Criteria:

\- Not applicable

Locations (1)

Princeton, New Jersey, United States